Sildenafil and Cardiomyocyte-specific CGMP Signaling Prevent Cardiomyopathic Changes Associated with Dystrophin Deficiency

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 May 14

PMID 18474859

Citations 53

Authors

M Khairallah

R J Khairallah

M E Young

B G Allen

M A Gillis

G Danialou

C F Deschepper

B J Petrof

C Des Rosiers

Affiliations

Soon will be listed here.

Abstract

We recently demonstrated early metabolic alterations in the dystrophin-deficient mdx heart that precede overt cardiomyopathy and may represent an early "subclinical" signature of a defective nitric oxide (NO)/cGMP pathway. In this study, we used genetic and pharmacological approaches to test the hypothesis that enhancing cGMP, downstream of NO formation, improves the contractile function, energy metabolism, and sarcolemmal integrity of the mdx heart. We first generated mdx mice overexpressing, in a cardiomyocyte-specific manner, guanylyl cyclase (GC) (mdx/GC(+/0)). When perfused ex vivo in the working mode, 12- and 20-week-old hearts maintained their contractile performance, as opposed to the severe deterioration observed in age-matched mdx hearts, which also displayed two to three times more lactate dehydrogenase release than mdx/GC(+/0). At the metabolic level, mdx/GC(+/0) displayed a pattern of substrate selection for energy production that was similar to that of their mdx counterparts, but levels of citric acid cycle intermediates were significantly higher (36 +/- 8%), suggesting improved mitochondrial function. Finally, the ability of dystrophin-deficient hearts to resist sarcolemmal damage induced in vivo by increasing the cardiac workload acutely with isoproterenol was enhanced by the presence of the transgene and even more so by inhibiting cGMP breakdown using the phosphodiesterase inhibitor sildenafil (44.4 +/- 1.0% reduction in cardiomyocyte damage). Overall, these findings demonstrate that enhancing cGMP signaling, specifically downstream and independent of NO formation, in the dystrophin-deficient heart improves contractile performance, myocardial metabolic status, and sarcolemmal integrity and thus constitutes a potential clinical avenue for the treatment of the dystrophin-related cardiomyopathies.

Citing Articles

Current Pharmacological Strategies for Duchenne Muscular Dystrophy.

Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G Front Cell Dev Biol. 2021; 9:689533.

PMID: 34490244 PMC: 8417245. DOI: 10.3389/fcell.2021.689533.

Cellular pathology of the human heart in Duchenne muscular dystrophy (DMD): lessons learned from in vitro modeling.

Svobodova B, Jelinkova S, Pesl M, Beckerova D, Lacampagne A, Meli A Pflugers Arch. 2021; 473(7):1099-1115.

PMID: 34169350 DOI: 10.1007/s00424-021-02589-0.

Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model.

Sullivan R, Lam N, Haberman M, Beatka M, Afzal M, Lawlor M BMC Cardiovasc Disord. 2021; 21(1):302.

PMID: 34130633 PMC: 8207777. DOI: 10.1186/s12872-021-02112-4.

Metformin Reverses the Enhanced Myocardial SR/ER-Mitochondria Interaction and Impaired Complex I-Driven Respiration in Dystrophin-Deficient Mice.

Angebault C, Panel M, Lacote M, Rieusset J, Lacampagne A, Fauconnier J Front Cell Dev Biol. 2021; 8:609493.

PMID: 33569379 PMC: 7868535. DOI: 10.3389/fcell.2020.609493.

Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy.

Gartz M, Lin C, Sussman M, Lawlor M, Strande J Dis Model Mech. 2020; 13(11).

PMID: 33188007 PMC: 7673361. DOI: 10.1242/dmm.045559.

References

Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O . Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005; 1(4):259-71. DOI: 10.1016/j.cmet.2005.03.002. View

Ockaili R, Salloum F, Hawkins J, Kukreja R . Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 2002; 283(3):H1263-9. DOI: 10.1152/ajpheart.00324.2002. View

Danialou G, Comtois A, Dudley R, Karpati G, Vincent G, Des Rosiers C . Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 2001; 15(9):1655-7. DOI: 10.1096/fj.01-0030fje. View

Hare J, Stamler J . NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest. 2005; 115(3):509-17. PMC: 1052013. DOI: 10.1172/JCI24459. View

Nakayama H, Chen X, Baines C, Klevitsky R, Zhang X, Zhang H . Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007; 117(9):2431-44. PMC: 1937500. DOI: 10.1172/JCI31060. View

Costa A, Garlid K, West I, Lincoln T, Downey J, Cohen M . Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res. 2005; 97(4):329-36. DOI: 10.1161/01.RES.0000178451.08719.5b. View

Stanley W, Recchia F, Lopaschuk G . Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005; 85(3):1093-129. DOI: 10.1152/physrev.00006.2004. View

Khairallah M, Khairallah R, Young M, Dyck J, Petrof B, Des Rosiers C . Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell Cardiol. 2007; 43(2):119-29. DOI: 10.1016/j.yjmcc.2007.05.015. View

Lau K, Grange R, Chang W, Kamm K, Sarelius I, Stull J . Skeletal muscle contractions stimulate cGMP formation and attenuate vascular smooth muscle myosin phosphorylation via nitric oxide. FEBS Lett. 1998; 431(1):71-4. DOI: 10.1016/s0014-5793(98)00728-5. View

10.

Qian C, Takahashi M, Kahnoski R, Teh B . Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model. J Urol. 2003; 170(3):994-7. DOI: 10.1097/01.ju.0000080321.99119.df. View

11.

Petrof B, Shrager J, Stedman H, Kelly A, Sweeney H . Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993; 90(8):3710-4. PMC: 46371. DOI: 10.1073/pnas.90.8.3710. View

12.

Chen Y, Zhao P, Borup R, Hoffman E . Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 2000; 151(6):1321-36. PMC: 2190600. DOI: 10.1083/jcb.151.6.1321. View

13.

Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn J, Yasuhara S . Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One. 2007; 2(8):e806. PMC: 1950086. DOI: 10.1371/journal.pone.0000806. View

14.

Sicinski P, Geng Y, Barnard E, Darlison M, Barnard P . The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989; 244(4912):1578-80. DOI: 10.1126/science.2662404. View

15.

Yasuda S, Townsend D, Michele D, Favre E, Day S, Metzger J . Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 2005; 436(7053):1025-9. DOI: 10.1038/nature03844. View

16.

Halcox J, Nour K, Zalos G, Mincemoyer R, Waclawiw M, Rivera C . The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002; 40(7):1232-40. DOI: 10.1016/s0735-1097(02)02139-3. View

17.

Bia B, Cassidy P, Young M, Rafael J, Leighton B, Davies K . Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol. 1999; 31(10):1857-62. DOI: 10.1006/jmcc.1999.1018. View

18.

Fiedler B, Lohmann S, Smolenski A, Linnemuller S, Pieske B, Schroder F . Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002; 99(17):11363-8. PMC: 123262. DOI: 10.1073/pnas.162100799. View

19.

Blake D, Weir A, Newey S, Davies K . Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002; 82(2):291-329. DOI: 10.1152/physrev.00028.2001. View

20.

Thomas G, Sander M, Lau K, Huang P, Stull J, Victor R . Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A. 1998; 95(25):15090-5. PMC: 24580. DOI: 10.1073/pnas.95.25.15090. View